Analysis of economic and social costs of adverse events associated with blood transfusions in Spain

Objective: To calculate, for the first time, the direct and social costs of transfusion-related adverse events in order to include them in the National Healthcare System's budget, calculation and studies. In Spain more than 1,500 patients yearly are diagnosed with such adverse events. Method: Blood transfusion-related adverse events recorded yearly in Spanish haemovigilance reports were studied retrospectively (2010-2015). The adverse events were coded according to the classification of Diagnosis-Related Groups. The direct healthcare costs were obtained from public information sources. The productivity loss (social cost) associated with adverse events was calculated using the human capital and hedonic salary methodologies. Results: In 2015,1,588 patients had adverse events that resulted in direct health care costs (4,568,914sic) and social costs due to hospitalization (200,724sic). Three adverse reactions resulted in patient death (at a social cost of 1,364,805sic). In total, the cost of blood transfusion-related adverse events was 6,134,443 in Spain. For the period 2010-2015: the trends show a reduction in the total amount of transfusions (2 vs. 1.91 M;-4.4%). The number of adverse events increased (822 vs. 1,588; +93%), as well as their related direct healthcare cost (3.22 vs. 4.57M sic; +42%) and the social cost of hospitalization (110 vs 200M sic; +83%). Mortality costs decreased (2.65 vs. 1.36M sic;-48%). Discussion: This is the first time that the costs of post-transfusion adverse events have been calculated in Spain. These new figures and trends should be taken into consideration in any cost-effectiveness study or trial of new surgical techniques or sanitary policies that influence blood transfusion activities. (C) 2018 SESPAS. Published by Elsevier Espana, S.L.U.